adalimumab products — Medica
ankylosing spondylitis
Initial criteria
- age ≥ 18 years
- prescribed by or in consultation with a rheumatologist
Reauthorization criteria
- patient established on therapy ≥ 6 months
- beneficial clinical response by objective measure OR improvement in symptom/function vs baseline
Approval duration
initial 6 months, reauth 1 year